HELX
Franklin Genomic Advancements ETF
HELX is an actively managed portfolio of global equity securities of companies relevant to genomic discovery.
Global
EQUITY
Active
MANAGEMENT STYLE
$ 20.0 M
ASSETS UNDER MGMT
50 bp
EXPENSES
Fund Basics
| Inception date | Feb 25, 2020 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| NATERA INC | 6.9 % |
| GUARDANT HEALTH, INC. | 6.8 % |
| KRYSTAL BIOTECH, INC. | 4.6 % |
| MEDPACE HOLDINGS, INC. | 4.4 % |
| INSMED INC | 4.4 % |
| BRIDGEBIO PHARMA, INC. | 3.9 % |
| ALNYLAM PHARMACEUTICALS INC | 3.6 % |
| UNITED THERAPEUTICS CORP | 3.5 % |
| ADAPTIVE BIOTECHNOLOGIES CORP. | 3.3 % |
| LIGAND PHARMACEUTICALS-CL B | 3.0 % |
Constituent Breakdown
| Number of holdings | 67 |
| Herfindahl-Hirschman Index | 300 |
| Wgt avg mkt cap (mns) | $57,914 |
| Large cap (>$10bn) | 63.4% |
| Mid cap ($2-10bn) | 25.6% |
| Small cap (<$2bn) | 2.9% |
| Developed mkts. | 94.5% |
| Emerging mkts. | 2.2% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 85.1 % |
 |
BRITAIN | 2.8 % |
 |
GERMANY | 2.8 % |
 |
NETHERLANDS | 2.3 % |
 |
SOUTH KOREA | 1.9 % |
 |
SWITZERLAND | 0.7 % |
 |
IRELAND | 0.6 % |
Historical Performance
Standardized Performance (as of 02/28/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -4.9% | 18.0% | 3.6% | 5.1% | -5.2% | -- | -- | 6.3% |
| Dividend Yield | 0.0% | 0.5% | 0.2% | 0.1% | 0.1% | -- | -- | 0.1% |
| Total Returns | -4.9% | 18.5% | 3.8% | 5.2% | -5.0% | -- | -- | 6.4% | Ann. Volatility | 20.6% | 23.7% | 21.2% | 20.2% | 25.0% | -- | -- | 27.4% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.90 | 53% |
| MSCI EAFE | 0.96 | 44% |
| MSCI Emg Mkts | 0.81 | 38% |
Liquidity Measures
| Avg. volume (000) | 1 |
| ADV traded (mns) | $0 |
| Turnover | 0.2% |
| Avg. Bid/Ask (% of price) | 0.45% |
Technical Indicators
| 30d moving avg. (EMA) | $34.31 |
| Relative strength (RSI) | 35 |
| MACD/Signal | -0.85/-0.71 |
| Bollinger Bands (Upper/Lower) | $35.79/$32.12 |
| Short interest (% of AUM) | 0.4% |
Distributions
Assets Under Management (mns)
Money Flows (mns)
Short Interest (as % of shares outstanding)
Long Money Flows (mns)
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. HELX |
Expenses vs. HELX |
ALTAR Score™ vs. HELX |
|---|---|---|---|---|
| WDNA | WisdomTree BioRevolution Fund | 31.0% | -5 bp | -2.1% |
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 30.0% | +10 bp | -0.3% |
| BBH | VanEck Biotech ETF | 28.7% | -15 bp | +5.6% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 27.9% | -31 bp | +1.3% |
| HTEC | ROBO Global Healthcare Technology and Innovation ETF | 27.8% | +18 bp | +3.5% |
| GNOM | Global X Genomics & Biotechnology ETF | 26.6% | 0 bp | -2.4% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 26.3% | +6 bp | +3.2% |
| IBB | iShares Biotechnology ETF | 26.1% | -5 bp | +0.5% |
| BMED | Future Health ETF | 23.2% | +35 bp | +2.0% |
| BBP | Virtus LifeSci Biotech Products ETF | 23.1% | +29 bp | -2.8% |
Risk and Returns: HELX vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 3/14/2026
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-1.0%
ALTAR SCORE™
2nd
PERCENTILE
AVOID
ETFRC RATING
There are 567 funds in the Global Equity category with an average
ALTAR Score™ of 4.6% and a standard deviation
of 2.7%. HELX's ALTAR Score™ is approximately -2.1 standard
deviations above the category average. This places HELX in the 2nd percentile
among funds in the category.
Sell-Side Consensus
$43.5
PRICE TARGET
+36.0%
UPSIDE